莫西沙星治疗慢性阻塞性肺疾病急性加重期有创机械通气患者的临床效果观察

目的观察莫西沙星治疗慢性阻塞性肺疾病急性加重期（AECOPD）有创机械通气患者的临床效果。方法将 60例AECOPD有创机械通气患者完全随机分成观察组和对照组，各30例。莫西沙星组静脉滴注莫西沙星治疗0.4 g，1次/d，治疗7～14 d；左氧氟沙星组静脉滴注左氧氟沙星，0.5 g，1次/d，治疗7～14 d。比较2组疗效、细菌清除率及脱呼吸机时间。结果莫西沙星组的临床有效率[83.3%（25/30）]、细菌清除率[86.7%（26/30）]、脱呼吸机成功率[76.7%（23/30）]均高于左氧氟沙星组[46.7%（14/30），53.3%（16/30），43.3%（13/30）] （P〈0.01或P〈0.05），莫西沙星组低血糖发生率较左氧氟沙星组低[3.0%（1/30）比23.3%（7/30）]，差异有统计学意义（P〈0.01）。结论莫西沙星治疗AECOPD有创机械通气患者的临床疗效优于左氧氟沙星，且不良反应发生率低。

Clinical observation of moxifloxacin in the treatment of acute exlosion chronic obstructive pulmonary disease patients with invasive mechanical ventilation

ObjectiveTo observe the clinical effects of moxifloxacin on acute exlosion chronic obstructive pulmonary disease（AECOPD） with invasive mechanical ventilation. MethodsSixty patients of AECOPD with invasive mechanical ventilation were randomly divided into two groups; they were treated with moxifloxacin and levofloxacin respectively. The efficacy rates,bacteriums eradication rates and the time detaching from the ventilator were compared. ResultsThe efficacy rates （83.3%,25/30）, bacteriums eradication rates （86.7%,26/30）, the success rate of detaching from the ventilator （76.7%,23/30） in moxifloxacin group were higher than those in the levofloxacin group／[46.7%（14/30）,53.3%（16/30）,43.3%（13/30）／] （P〈0.01 or P〈0.05）, the incidence of adverse drug reactions in moxifloxacin group lower than that in the levofloxacin group／[3.0%（1/30） vs 23.3%（7/30）／], with statistical significance（P〈0.01）.ConclusionIn the treatment of AECOPD that need for invasive mechanical ventilation patients, moxifloxacin has good clinical efficacy.